Fagron Revenue and Competitors
Estimated Revenue & Valuation
- Fagron's estimated annual revenue is currently $14.1M per year.
- Fagron's estimated revenue per employee is $201,000
Employee Data
- Fagron has 70 Employees.
- Fagron grew their employee count by 1% last year.
Fagron's People
Name | Title | Email/Phone |
---|---|---|
1 | VP, Sales Operations B&E | Reveal Email/Phone |
2 | Senior Director Marketing | Brands & Essentials | Reveal Email/Phone |
3 | Quality Director | Reveal Email/Phone |
4 | Senior Director Professional Services | Reveal Email/Phone |
5 | R&D Manager | Reveal Email/Phone |
6 | Customer Account and Pricing Specialist | Reveal Email/Phone |
7 | Sales Director | Reveal Email/Phone |
8 | Information Technology Business Analyst | Reveal Email/Phone |
9 | SALES REPRESENTATIVE / ACCOUNT MANAGER | Reveal Email/Phone |
10 | Accounting Professional | Reveal Email/Phone |
Fagron Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $85.6M | 426 | 8% | N/A | N/A |
What Is Fagron?
Follow us on Twitter: @FagronUS Like us on Facebook: Fagron US Follow us on Instagram: @fagron_us Fagron, Inc. - USA Fagron's strategy is focused on the optimization and innovation of pharmaceutical compounding. As an R&D scientific pharmaceutical compounding supplier, Fagron wants to widen the therapeutic scope of the prescriber to enable tailor-made pharmaceutical care. Through its activities, Fagron supports the unique selling point of the pharmacist. Fagron, Inc., is headquartered in St. Paul, Minnesota. The company has continued to grow through the years because of its innovation and ability to bring new products to the U.S. compounding market. Since 1980, Fagron, Inc. has been a US Food and Drug Administration-registered pharmaceutical supplier, adhering strictly to current Good Manufacturing Practices (cGMP). Bulk Pharmaceutical Ingredients (BPI) are purchased from reputable, registered, and validated manufacturers. Incoming BPIs are initially quarantined, then sampled and tested for identity, strength, quality, and purity in our Quality Control Laboratories, using methods as set forth in the applicable monographs of USP, NF, British Pharmacopoeia (BP), or European Pharmacopoeia (EP). Repackaging is performed in our climate-monitored facility, then retested by Quality Control (QC) and reviewed by Quality Assurance (QA) before release to the market.
keywords:N/AN/A
Total Funding
70
Number of Employees
$14.1M
Revenue (est)
1%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Fagron News
Fagron, the leading global player in pharmaceutical compounding, today publishes its quarterly results for the period ending 31 March 2022.
The Board of Directors of Fagron NV (Fagron) invites the holders of shares and subscription rights of Fagron to attend the annual general...
What Does The Institutional Ownership Tell Us About Fagron? Institutional investors commonly compare their own returns to the returns of a...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $22.2M | 70 | 0% | N/A |
#2 | $12.7M | 70 | 6% | N/A |
#3 | $11.5M | 71 | -5% | N/A |
#4 | $15.5M | 71 | 3% | N/A |
#5 | $13.4M | 71 | 4% | N/A |